Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03220477
Recruitment Status : Active, not recruiting
First Posted : July 18, 2017
Last Update Posted : August 6, 2021
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
Astex Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Stand Up To Cancer
Van Andel Research Institute
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2022